HUA LEIN PHARMACEUTICAL-B (STOCK CODE: 2552) ISSUED A SUPPLEMENTAL NOTICE ON 15 MARCH 2024 DETAILING THE INFORMATION REGARDING THE APPOINTMENT OF DR. CHEUNG YI AS EXECUTIVE DIRECTOR FROM 1 JANUARY 2024. The announcement is supplemented by the provision of approximately 1.10% of Dr. Zhang's shares in the Company, including shares directly held and share purchase rights granted under the Company's Share Incentive Program. Dr. Zhang confirms that no other information is required to be disclosed in accordance with the Listing Rules and that no other matters should be brought to the attention of shareholders other than the disclosed information. Other information in this announcement remains unchanged.

HUA LEIN PHARMACEUTICAL-B (STOCK CODE: 2552) ISSUED A SUPPLEMENTAL NOTICE ON 15 MARCH 2024 DETAILING THE INFORMATION REGARDING THE APPOINTMENT OF DR. CHEUNG YI AS EXECUTIVE DIRECTOR FROM 1 JANUARY 2024. The announcement is supplemented by the provision of approximately 1.10% of Dr. Zhang's shares in the Company, including shares directly held and share purchase rights granted under the Company's Share Incentive Program. Dr. Zhang confirms that no other information is required to be disclosed in accordance with the Listing Rules and that no other matters should be brought to the attention of shareholders other than the disclosed information. Other information in this announcement remains unchanged.